MAPT and Alzheimer disease: TLB:Protects 3xFAD AD model mice against Aβ burden, neuroinflammation, tau hyperphosphorylation, synaptic degeneration, hippocampal neuronal loss, and memory impairment.Suppresses glial activation by inhibiting the TLR4-MYD88-NFκB pathway, leading to a reduction in inflammatory factors TNF-α, IL-1β, and IL-6.Ameliorates cognitive deficits.Reduces tau and Aβ pathology.Modulates spine plasticity.Protects against neuronal loss, and inhibited gliosis.